Bone Biologics Corp Net Income Loss

• Bone Biologics Corp showed an increase of +24.4% in Net Income Loss from 2024 to 2025.
• This data is from Bone Biologics Corp's annual report (Form 10-K), filed with the SEC on March 2, 2026.
• XBRL data for this metric is available from 2007 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 20 years of available data (2007 to 2025), Bone Biologics Corp's Net Income Loss has declined by 14,146.4%.
• Historical annual values: Fiscal year 2025: -$3.11 million | Fiscal year 2024: -$4.11 million | Fiscal year 2023: -$8.95 million | Fiscal year 2022: -$1.48 million | Fiscal year 2021: -$1.61 million | Fiscal year 2020: -$1.82 million | Fiscal year 2019: -$3.42 million | Fiscal year 2018: -$4.43 million | Fiscal year 2017: -$7.05 million | Fiscal year 2016: -$25.88 million | Fiscal year 2015: -$13.88 million | Fiscal year 2014: -$4.42 million | Fiscal year 2013: -$1.08 million | Fiscal year 2013: -$5.2 thousand | Fiscal year 2012: -$5.6 thousand | Fiscal year 2011: -$4.9 thousand | Fiscal year 2010: -$3.6 thousand | Fiscal year 2009: -$10.3 thousand | Fiscal year 2008: -$13.3 thousand | Fiscal year 2007: -$21.8 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026